BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 1825969)

  • 1. Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months.
    Dibbelt L; Knuppen R; Jütting G; Heimann S; Klipping CO; Parikka-Olexik H
    Contraception; 1991 Jan; 43(1):1-21. PubMed ID: 1825969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
    Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A
    Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
    Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein binding of the contraceptive steroids gestodene, 3-keto-desogestrel and ethinylestradiol in human serum.
    Kuhnz W; Pfeffer M; al-Yacoub G
    J Steroid Biochem; 1990 Feb; 35(2):313-8. PubMed ID: 2308344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of serum ethinyl estradiol, sex-hormone-binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral contraceptives.
    Hümpel M; Tüber U; Kuhnz W; Pfeffer M; Brill K; Heithecker R; Louton T; Steinberg B
    Horm Res; 1990; 33(1):35-9. PubMed ID: 2142929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
    Hammond GL; Langley MS; Robinson PA; Nummi S; Lund L
    Fertil Steril; 1984 Jul; 42(1):44-51. PubMed ID: 6233179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Staks T; Jütting G
    Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
    Wiegratz I; Jung-Hoffmann C; Kuhl H
    Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene.
    Hammond GL; Bocchinfuso WP; Orava M; Smith CL; van den Ende A; van Enk A
    Contraception; 1994 Oct; 50(4):301-18. PubMed ID: 7813219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein binding of active ingredients and comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ethinyl estradiol (Femovan) or a combination of desogestrel/ethinyl estradiol (Marvelon) and single-dose ethinyl estradiol bioequivalence from both oral contraceptives.
    Hümpel M; Täuber U; Kuhnz W; Pfeffer M; Brill K; Heithecker R; Louton T; Steinberg B; Seifert W; Schütt B
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):329-33. PubMed ID: 2142574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
    Kuhnz W; al-Yacoub G; Fuhrmeister A
    Contraception; 1992 Nov; 46(5):455-69. PubMed ID: 1458892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
    Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
    Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
    Jung-Hoffmann C; Fitzner M; Kuhl H
    Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women.
    Paoletti AM; Orrù M; Floris S; Mannias M; Vacca AM; Ajossa S; Guerriero S; Melis GB
    Contraception; 2000 Apr; 61(4):259-63. PubMed ID: 10899481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin.
    Bergink W; Assendorp R; Kloosterboer L; van Lier W; Voortman G; Qvist I
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2132-7. PubMed ID: 2147817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel.
    Gaspard UJ; Romus MA; Gillain D; Duvivier J; Demey-Ponsart E; Franchimont P
    Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and protein binding of gestodene under treatment with a low-dose combination oral contraceptive for three months.
    Dibbelt L; Knuppen R; Kuhnz W; Jütting G
    Arzneimittelforschung; 1992 Sep; 42(9):1146-52. PubMed ID: 1445484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex hormone binding globulin, cortisol binding globulin, thyroxine binding globulin, ceruloplasmin: changes in treatment with two oral contraceptives low in oestrogen.
    Sobbrio GA; Granata A; Granese D; D'Arrigo F; Panacea A; Nicita R; Pullè C; Trimarchi F
    Clin Exp Obstet Gynecol; 1991; 18(1):43-5. PubMed ID: 1829029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in androgens during treatment with four low-dose contraceptives.
    Coenen CM; Thomas CM; Borm GF; Hollanders JM; Rolland R
    Contraception; 1996 Mar; 53(3):171-6. PubMed ID: 8689882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.